This new deal will allow CVS to coordinate medical care for millions of Americans through 10,000 contracted doctors and clinicians across 50 states. Furthermore, CVS Health President and CEO Karen S. Lynch claimed that the combination of these two entities would enhance their connection to consumers.
CVS chart and analysis
CVS is part of the Health Care Providers & Services industry, with 127 other stocks in this industry, it outperforms 87% of them. Over the past month, the stock traded from $97.75 to $107.26, closing above the 50-day moving average. Further, the technical analysis shows a support line at $92.87 and a resistance line at $106.61. TipRanks analysts rate the shares a ‘strong buy,’ seeing the average price in the next 12 months reaching $122.33, 23.02% higher than the current trading price of $99.44. Out of the 12 TipRanks analysts covering the stock, ten have a ‘buy,’ and only two have a ‘hold’ rating.
Innovation experts.
With this acquisition, CVS keeps piling on innovation and showing that they’re a responsible custodian of human health, which was confirmed by their more recent acquisition of green, renewable energy from Constellation (NASDAQ: CEG), a 15-year commitment by CVS. All in all, CVS is becoming a healthcare behemoth in its industry, with a 2.21% dividend yield, or $0.55 quarterly per share, it could find its place on the list of dividend investors’ potential plays. Buy stocks now with Interactive Brokers – the most advanced investment platform Disclaimer: The content on this site should not be considered investment advice. Investing is speculative. When investing, your capital is at risk.
